Serina Therapeutics (SER) 10-Q2023 Q2 Quarterly report

Filed: 14 Aug 23, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Bad

New words: academia, academic, accident, adjudication, advisory, announcement, Artery, Asia, bankrupt, bear, Biocapital, Blood, broker, brought, Brunswick, Bryan, Bulletin, Cambridge, cancellation, cancelled, Catapult, certainty, certificate, certified, Chair, Chairperson, Cite, Cognate, confidential, confidentiality, conflict, construed, conveyance, copy, creation, customary, Dartmouth, death, degree, delivering, Department, disability, dissolution, Dr, eligible, England, Europe, evidence, exclusive, Exhibit, expertise, fifteen, fill, firm, fostering, Fourth, fractional, Garnier, Genomic, Hackett, healthcare, hearing, Heart, improper, incapacitated, inconvenient, industry, innovative, insufficient, involuntarily, IQVIA, irrevocably, Joanne, joined, July, junior, Kingdom, Lead, leader, London, long, Lung, mail, mailing, MBA, MD, medicine, Michael, Molecular, newly, ninety, Nominating, North, Oman, outsourcing, overnight, parity, parri, Partner, passu, pension, Peripheral, PhD, precision, prevailing, proportion, proportionately, purport, rare, ratably, reclassify, referenced, Renondin, resolution, retirement, River, SAB, salary, Scalable, School, scientist, scrip, sequencing, serve, served, serving, sitting, Sovereign, spread, stepped, strategy, subdivide, subdivision, testing, therapy, Tuck, Universite, unused, vacancy, venture, venue, Viscogliosi, voluntarily, voluntary, West, wider, winding, window, withdrew, withholding, workforce

Removed: applied, averaged, bid, bring, delisted, illegal, interdealer, judgement, monitoring, quotation, regained, revised, system, twenty, undischarged, updated, xi, xii, xiii

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SER similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of AgeX Therapeutics, Inc. (the “Company”) for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Joanne M. Hackett, Interim Chief Executive Officer, and Andrea E. Park, Chief Financial Officer, of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2023

/s/ Joanne M. Hackett
Joanne M. Hackett
Interim Chief Executive Officer

/s/ Andrea E. Park
Andrea E. Park
Chief Financial Officer